Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (<scp>PNH</scp>): Pooled Results From the Phase 3 <scp>COMMODORE</scp> Studies
Crovalimab's safety profile was consistent with eculizumab's and was generally comparable between C5i-naive and C5i-switched patients.
Authors
- Muriel Buri (ORCID: https://orcid.org/0000-0001-7432-4874)
- Guangsheng He (ORCID: https://orcid.org/0000-0002-3944-5897)
- Nicolò Compagno (ORCID: https://orcid.org/0000-0002-7590-4093)
- Phillip Scheinberg (ORCID: https://orcid.org/0000-0002-9047-4538)
- Sasha Sreckovic
- Simon Buatois (ORCID: https://orcid.org/0000-0002-1472-5366)
- Viviane Lacorte Recôva
- Michihiro Uchiyama
- Yosr Hicheri (ORCID: https://orcid.org/0000-0002-4508-9921)
- Sheng‐Chieh Chou (ORCID: https://orcid.org/0000-0002-4121-019X)
- Alexander Röth (ORCID: https://orcid.org/0000-0003-4414-7699)
- Nadiesh Balachandran
- Hazzaa Alzahrani (ORCID: https://orcid.org/0000-0002-5596-8807)
- Leigh Beveridge
- Rong Fu (ORCID: https://orcid.org/0000-0002-9928-9224)
- Maciej Kaźmierczak (ORCID: https://orcid.org/0000-0003-4382-1602)
- Ana‐Maria Vladareanu
- Dayu Shi (ORCID: https://orcid.org/0009-0007-7202-7391)
Institutions
- Roche (Switzerland) (CH)
- Poznan University of Medical Sciences (PL)
- Clinical Emergency Hospital Bucharest (RO)
- King Faisal Specialist Hospital & Research Centre (SA)
- Tianjin Medical University General Hospital (CN)
- Roche (United Kingdom) (GB)
- Beneficência Portuguesa de São Paulo (BR)
- Roche (China) (CN)
- National Taiwan University Hospital (TW)
- Institut Paoli-Calmettes (FR)
- Jiangsu Province Hospital (CN)
- Suwa Red Cross Hospital (JP)
- Bucharest Emergency University Hospital
- University of Duisburg-Essen (DE)
- Nanjing Medical University (CN)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1111/ejh.14339
- Citations
- 3
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- F. Hoffmann-La Roche
- Universität Duisburg-Essen
- Chugai Pharmaceutical